Blueprint’s Evolution On Its Path To Financial Sustainability
Executive Summary
Chief operating officer Christina Rossi talked to Scrip about the company’s new blockbuster-sized commercial opportunity for Ayvakit and the company’s next phase: financial sustainability.
You may also be interested in...
Q3 Earnings: Surveying The Small Biopharma Launch Scene
Several small biopharmas are launching new drugs independently, sales of some of those drugs appear to be off to a slow start.
Blueprint Sees Blockbuster Potential For Ayvakit In Systemic Mastocytosis With ISM Nod
The US FDA gave the drug a broad label in adults with indolent SM, without restrictions for disease severity or prior treatment, and Blueprint sees a potential $1.5bn market opportunity.
Blueprint Prepares To Take On Novartis In Advanced Systemic Mastocytosis
The company’s rollout plans for Ayvakit appear similar to its approach when it marketed the drug for GIST, with an education plan to help boost sales.